Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ingredient Safety Concerns Rise Among FDA Enforcement Priorities

This article was originally published in The Tan Sheet

Executive Summary

Ingredient safety, new dietary ingredient notifications, adverse event reporting, claims substantiation and disease claims are all drawing FDA attention in the supplement space, Daniel Fabricant says. Compliance for good manufacturing practices still heads the priorities for enforcement, he says.

You may also be interested in...



Medical Foods No “Dumping Ground” For Disease Claims – FDA

FDA’s Dan Fabricant warns placing a medical food label on a dietary supplement constrained by structure/function claims does not make disease claims for the product legal. He says the agency is cracking down on products mislabeled as medical foods and on medical foods making disease claims.

Medical Foods No “Dumping Ground” For Disease Claims – FDA

FDA’s Dan Fabricant warns placing a medical food label on a dietary supplement constrained by structure/function claims does not make disease claims for the product legal. He says the agency is cracking down on products mislabeled as medical foods and on medical foods making disease claims.

In Brief: FDA responds to Nasacort suit, acts on acetaminophen and continues medical food enforcement

FDA responds to Nasacort Allergy suit; FDA will act on lower acetaminophen dose; FDA warns consumers about wart removers; FDA continues medical food enforcement; Supplements must include declared ingredients; CHPA applauds DXM-related legislation; and USP opens Shanghai facility.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS106620

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel